Summary of Kangyuan Pharmaceutical Conference Call Company Overview - **Company**: Kangyuan Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on traditional Chinese medicine and innovative drugs Key Points Financial Performance - In 2025, Kangyuan Pharmaceutical experienced a decline in revenue and sales profit, with net profit decreasing by 30% compared to the previous year. However, the fourth quarter saw significant growth in flu-related products and other major products, which helped narrow the overall decline in revenue and profit for the year [4][2]. Organizational Changes - The company has restructured its organization by establishing a Cardiovascular Division and a Sunshine Division. This aims to focus on the development of core products like Ginkgo and Tianshu, as well as new retail OTC channels, to promote a diverse portfolio of innovative drugs by 2026 [2][4]. Product Pipeline and Market Strategy - Kangyuan Pharmaceutical anticipates that 5 to 6 key products will likely enter the essential drug list, primarily in pediatrics and cardiovascular fields, which will help the company quickly capture market share in grassroots markets [2][5][6]. - The company is actively addressing the impact of DRG/DIP payment policies by enhancing academic promotion and advancing innovative product combinations to stabilize revenue and profit [2][13]. Clinical Trials and Innovations - The company is making progress in clinical trials for its three-target and two-target diabetes drugs, expecting to complete Phase II trials and read data by May 2026, indicating strong market potential [2][11]. - The first biological innovative drug, ZHONGXING 1,305 eye drops, is expected to be launched in 2027, with a concentrated period of innovative drug launches planned for 2028-2029 [3][15]. Regulatory Environment - The adjustment of the essential drug list policy emphasizes prioritizing innovative drugs and strengthening evidence-based medicine research. Kangyuan Pharmaceutical believes it has a competitive advantage in this area due to its commitment to clinically valuable innovation [5][9]. Market Outlook - The company aims for a rebound in 2026 after a challenging 2025, with a focus on core products and a sales strategy to achieve growth and address investor concerns [8][17]. - Kangyuan Pharmaceutical is also preparing for the commercialization of new drugs, with plans to increase R&D funding and potentially consider strategic partnerships to meet future funding needs [15]. Challenges and Opportunities - The new regulations for traditional Chinese medicine are seen as a positive signal for industry development, although they may pose risks for smaller companies. Kangyuan Pharmaceutical views this as an opportunity to increase industry concentration [9][10]. Future Expectations - Despite the setbacks in 2025, Kangyuan Pharmaceutical plans to leverage its strengths and enhance collaboration and R&D investments to achieve better results in 2026 [17]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, product pipeline, and market outlook.

Investment Rating - The report maintains a "Recommended" rating for Kangyuan Pharmaceutical with a target price of 20.8 CNY [2][7]. Core Views - The company's performance is under short-term pressure due to marketing reforms and demand fluctuations, with 1H25 revenue at 1.64 billion CNY (-27.3% YoY) and net profit at 140 million CNY (-40.1% YoY) [2][7]. - Despite the challenges, the company is making steady progress in R&D, with several new drugs in various stages of clinical trials [2][7]. - The report anticipates a new development cycle driven by marketing efficiency reforms and breakthroughs in innovative drugs [2][7]. Financial Summary - **Revenue and Profitability**: - Total revenue for 2024 is projected at 3.898 billion CNY, with a YoY growth rate of -19.9%. For 2025, revenue is expected to remain flat at 3.897 billion CNY, followed by growth of 10.0% in 2026 and 10.1% in 2027 [2][8]. - Net profit for 2024 is estimated at 392 million CNY, with a YoY decline of -27.0%. The net profit is expected to stabilize in 2025 and grow by 15.0% in 2026 and 15.1% in 2027 [2][8]. - **Earnings Per Share (EPS)**: - EPS is projected to be 0.69 CNY in 2024, remaining the same in 2025, and increasing to 0.80 CNY in 2026 and 0.92 CNY in 2027 [2][8]. - **Valuation Ratios**: - The price-to-earnings (P/E) ratio is expected to be 25 in 2025, decreasing to 22 in 2026 and 19 in 2027. The price-to-book (P/B) ratio is projected to decline from 2.0 in 2025 to 1.7 in 2027 [2][8]. R&D Progress - The company has made significant advancements in its R&D pipeline, with multiple new drugs in various clinical phases, including traditional Chinese medicine and chemical drugs [2][7]. - Notable projects include the approval of Yunu Jian granules and several new drug applications, with a focus on obesity and Alzheimer's disease treatments [2][7].

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Views - The company experienced significant revenue and profit pressure in the first half of 2025, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items declining by 27%, 40%, and 46% year-on-year, respectively [1][2]. - Despite the current challenges, the company is expected to gradually narrow the revenue decline, with potential growth from its traditional Chinese medicine, biopharmaceuticals, and chemical drugs pipelines [1][2]. - The collaboration with Dong'e Ejiao to promote Huangqi Essence is anticipated to unlock market potential, leveraging Dong'e Ejiao's strong marketing and distribution capabilities [4]. Summary by Sections Financial Performance - In 1H25, the company's revenue was 1.64 billion RMB, with a net profit of 140 million RMB and a net profit excluding non-recurring items of 120 million RMB, reflecting a year-on-year decline of 27%, 40%, and 46%, respectively [1]. - In 2Q25, revenue was 764 million RMB, with a net profit of 59 million RMB and a net profit excluding non-recurring items of 38 million RMB, showing declines of 15%, 42%, and 53% year-on-year [1]. Product Performance - Core products faced sales pressure, with injection revenue down 40% to 510 million RMB and oral liquid revenue down 49% to 280 million RMB in 1H25 [2]. - Other dosage forms showed mixed performance, with capsules and granules experiencing declines of approximately 5% and 18%, while tablets, patches, and gels saw growth of 5% to 12% [2]. Research and Development - The company has a robust R&D pipeline, with two approved traditional Chinese medicines and several in various clinical trial phases [5]. - The acquisition of Zhongxin Pharmaceutical is expected to enhance the company's product offerings, particularly in diabetes treatment with unique dual-target and triple-target products [3]. Valuation and Forecast - The revenue forecast for 2025-2027 has been adjusted downwards by 8%, 11%, and 13%, respectively, with expected net profits of 400 million RMB, 460 million RMB, and 530 million RMB, reflecting year-on-year growth of 2%, 15%, and 15% [6]. - The target price is set at 21.26 RMB, based on a 30x PE for 2025, indicating a premium over the average PE of comparable companies [6].